INBX
$69.71
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate ...
Recent News
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the best emerging technology stocks to invest in. On December 16, Inhibrx Biosciences provided a comprehensive progress update regarding its primary oncology programs. The company is currently advancing two lead therapeutic candidates: INBRX-106, which is a hexavalent sdAb-based OX40 agonist, and ozekibart (INBRX-109), which is a tetravalent death […]
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates
Inhibrx Biosciences (INBX) just put fresh clinical trial milestones on the table, updating investors on INBRX-106 combinations with Keytruda and advancing ozekibart toward potential FDA talks on an accelerated approval path in 2026. See our latest analysis for Inhibrx Biosciences. The steady string of trial updates seems to be feeding real momentum, with a recent 1 month share price return of 7.1 percent, building on a substantial 90 day share price return of 201 percent and a 1 year total...
Evaluating Inhibrx Biosciences (INBX) Valuation Following Breakthrough Phase 2 Results for Ozekibart
Inhibrx Biosciences (INBX) drew considerable attention after announcing that its lead candidate, ozekibart, delivered a clear progression-free survival benefit in advanced or metastatic chondrosarcoma during its latest Phase 2 study. This result is especially relevant because ozekibart is now the first investigational therapy to achieve such an outcome in this rare cancer. Patients previously had no systemic treatment options. Interim data in colorectal cancer and Ewing sarcoma further fueled...
Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory
If ozekibart secures FDA clearance, it would become the first targeted therapy approved for chondrosarcoma.
Inhibrx shares surge after bone cancer drug slows disease progression in trial
(Reuters) -Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in